The Use of Inhaled Corticosteroids in the Treatment of Asthma is Children in the Emergency Room
Status:
Completed
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
Asthma is the most common chronic illness of childhood. About 10% of children are affected.
Not surprisingly, acute asthma exacerbations are one of the common reasons to visit pediatric
emergency rooms (ER). About 5.7% of all pediatric emergency room visits are due to acute
asthma exacerbation. Around 8% of those get admitted to the hospital. This constitutes huge
financial and administrative burden on the health care system.
Inhaled corticosteroids (ICS) is the gold standard prophylactic therapy for patients with
persistent asthma. In the setting of acute asthma exacerbation systemic steroids given early
in the course of treatment help decrease the rate of admission and return to the ER. However,
the anti-inflammatory action of corticosteroids, through which this effect is caused, takes 4
hours to start working. This is because it is mediated through genomic pathways where the
transcription of several inflammatory cytokines is suppressed. It was also shown that
corticosteroids can cause vasoconstriction through non-genomic pathways. The onset of this
action is as quick as 30-60 minutes. It is proposed that this action is mediated by blocking
the extraneuronal uptake (metabolism) of norepinephrine in vascular smooth muscle cells,
hence, making it available for re-use by the sympathetic neuronal cells.
Our objective is to compare the efficacy of adding repetitive sequential doses of budesonide
versus placebo (normal saline (NS)) to β2-agonist and ipratropium bromide (IB) combination
(standard treatment) in the management of acute asthma in children in the ER. We hypothesize
that the addition of budesonide to β2-agonist and IB in the management of moderate to severe
acute asthma in the ER is superior to the addition of placebo.